Clinical Trial Update: Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dalteparin, lenalidomide, and low-dose dexamethasone in previously untreated multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• FRAGMIN (DALTEPARIN SODIUM)
• Revlimid (lenalidomide)

Snippet

Sponsor: University of Southern California | Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma | Phase 2 | Status: TERMINATED